The KDM1A Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma epithelial cells, engineered for loss-of-function studies of the KDM1A gene. This heterogeneous knockout pool is generated by Cas9-mediated gene disruption, yielding a diverse array of editing-induced alleles. The polyclonal format provides a genetically mosaic model that is well suited for pooled functional screens and bulk assays, minimizing clonal variation artifacts. The product is supplied as a growing culture for immediate use in downstream applications.
The A-549 host cell line originates from human lung adenocarcinoma tissue and is widely used as an epithelial model for non-small cell lung cancer research. These adherent cells harbor mutations in KRAS and TP53, reflecting common genetic alterations in lung adenocarcinoma, and exhibit robust proliferation. They are extensively employed in studies of oncogenic signaling, drug sensitivity, apoptosis, and metastatic behavior, offering a physiologically relevant system for investigating epigenetic regulators in lung cancer.
KDM1A (LSD1) is a flavin-dependent histone demethylase that removes mono- and dimethyl marks from H3K4 (H3K4me1/2), thereby functioning as a transcriptional corepressor. It is regulated by upstream signals from androgen and estrogen receptors, TGF-??, and PKC, and forms complexes with CoREST (RCOR1), HDAC1/2, and SNAI1. KDM1A represses tumor suppressor genes including CDKN1A (p21) and CDH1 (E-cadherin), and also demethylates non-histone substrates such as TP53, impacting cell cycle progression, apoptosis, and epithelial-mesenchymal transition. Its disruption leads to derepression of these targets, promoting growth arrest and loss of invasive capacity.
In the A-549 adenocarcinoma context, loss of KDM1A demethylase activity results in accumulation of H3K4me2 marks at promoters of genes like CDKN1A, driving their transcriptional activation and consequent cell cycle inhibition and apoptosis. Wild-type TP53 in these cells amplifies the growth-suppressive effect. Additionally, reactivation of CDH1 counteracts SNAI1-mediated EMT, reducing metastatic potential. These cellular phenotypes make this knockout model a powerful system for elucidating KDM1A-dependent epigenetic mechanisms in lung adenocarcinoma and for validating therapeutic strategies targeting LSD1.
Researchers can use these polyclonal cells in a variety of assays, including RT-qPCR and RNA-seq for transcriptomic profiling, ChIP-qPCR to measure H3K4me2 levels at specific loci, and Western blotting to confirm protein expression changes. Functional studies such as flow cytometry-based cell cycle and Annexin V apoptosis assays, along with Transwell migration/invasion experiments, enable quantitative assessment of phenotypic outcomes. The polyclonal population is also ideal for dose?Cresponse studies with LSD1 inhibitors (e.g., GSK-LSD1, ORY-1001) to explore drug efficacy and resistance mechanisms. For additional information, please contact Ascent Research.
